药物安全的经济学:用于评估电子药物系统的成本效益分析框架
Virginia Mumford1, Magdalena Z Raban1, Ling Li1
1Australian Institute of Health Innovation, Macquarie University, NSW, Australia.
Studies in health technology and informatics
|January 25, 2024
概括
在儿科医院实施电子药物系统 (EMS) 可以减少药物错误. 这项研究开发了一个成本效益分析框架,以评估EMS的净社会效益,包括患者和家庭的影响.
科学领域:
- 医疗信息学 医疗信息学
- 儿科药理学 儿科药理学
- 卫生经济学 卫生经济学
背景情况:
- 儿科药物处方是复杂的,与年龄和体重相关的剂量要求有助于持续的错误.
- 电子药物系统 (EMS) 通过诸如剂量计算器和计算机决策支持等功能提供潜在的解决方案.
- 关于EMS实施的成本效益分析的证据有限,特别是在儿科环境中.
研究的目的:
- 开发一个全面的成本效益分析 (CBA) 框架,用于评估儿童三级医院的EMS实施.
- 纳入卫生系统影响和患者/家庭网络影响,以进行净社会效益评估.
- 测量非临床自付费用的影响,并量化患者/社区对药物安全性的评估.
主要方法:
- 开发一种针对儿科护理中的EMS而定制的新型CBA框架.
- 包括社会视角,包括卫生系统,患者和家庭网络影响.
- 利用离散选择实验来评估与药物相关的危害以及药物安全的感知重要性.
主要成果:
- 该研究概述了评估EMS实施的多方面的影响的框架.
- 它强调了考虑非临床成本和患者报告的结果的重要性.
- 该框架允许在直接医疗保健成本之外进行全面评估.
结论:
- 一个强大的CBA框架对于理解儿科医院EMS的真正价值至关重要.
- 纳入患者和家庭的观点提供了一个更完整的社会效益评估.
- 这种方法可以指导有关采用技术的决策,以提高儿科药物安全性.
相关概念视频
01:19Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833
01:30Health Information Technology and Healthcare Information System
841
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
841
01:30Methods of Documentation VII: EMR
836
Electronic Medical Records (EMRs) primarily center around electronically documenting patients' health information within a single healthcare organization or practice. They contain essential clinical data related to a patient's medical history, diagnoses, medications, treatment plans, lab results, and other pertinent information relevant to the specific encounter or episode of care. EMRs are designed to streamline documentation and workflow processes within individual healthcare...
836
01:25Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
01:12Analysis of Population Pharmacokinetic Data
257
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
257
01:03Drug Control Governance: Regulatory Bodies and Their Impact
160
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
160